$28.05
1.44%
Nasdaq, Nov 19, 04:00 pm EST. Closed.

Adaptive Biotechnologies Corp Stock price

$28.05
+4.10 17.12% 1M
+15.09 116.44% 6M
+11.81 72.72% YTD
+12.90 85.15% 1Y
+23.61 531.76% 3Y
+0.70 2.56% 5Y
+8.05 40.25% 10Y
+8.05 40.25% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.41 1.44%

Is Adaptive Biotechnologies Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.6b
Enterprise Value
$4.6b
Net debt
positive
Cash
$344.3m
Shares outstanding
159.1m
Valuation
P/E
negative
P/S | estimate
15.0 | 14.9
EV/Sales | estimate
14.9 | 14.9
EV/FCF | ex SBC
negative | negative
P/B
32.2
Financial Health
Equity Ratio
42.7%
Return on Equity
-27.2%
ROCE
-6.6%
ROIC
-
Debt/Equity
2.3
Share-Based Compensation & Dilution
SBC | % of Revenue
$49.0m | 15.9%
SBC as % of FCF
-
SBC Growth 1Y
-5.5%
Share Count Growth 1Y
4.5%
Shareholder Yield
-4.5%
Financials
Revenue | estimate
$308.1m | $309.3m
EBITDA
$-27.9m
EBIT
$-36.7m
Net Income
$-63.9m
Free Cash Flow | ex SBC
$-24.0m | $-73.1m
Growth
Revenue | estimate
50.1% | 11.7%
EBITDA
74.8%
EBIT
69.8%
Net Income
47.4%
Free Cash Flow
70.8%
Margin
Gross
75.6%
EBITDA
-9.1%
EBIT
-11.9%
Net
-20.7%
Free Cash Flow | ex SBC
-7.8% | -23.7%
More
EPS
$-0.4
FCF per Share
$-0.2
Short interest
8.9%
Employees
624
Rev per Employee
$440.0k

Adaptive Biotechnologies Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Adaptive Biotechnologies Corp forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Adaptive Biotechnologies Corp forecast:

Buy
87%
Hold
13%

Adaptive Biotechnologies Corp Events

Past Events
NOV
4
Q3 2026 Earnings Call
15 days ago
SEP
15
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
JUL
29
Q2 2026 Earnings Call
4 months ago
MAY
5
Q1 2026 Earnings Call
7 months ago
FEB
5
Q4 2025 Earnings Call
10 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
NOV
5
Q3 2025 Earnings Call
about one year ago

Financial data from Adaptive Biotechnologies Corp

Jun '26
+/-
%
308 308
50% 50%
100%
- Direct Costs 75 75
8% 8%
24%
233 233
72% 72%
76%
- Selling and Administrative Expenses 180 180
13% 13%
59%
- Research and Development Expense 80 80
7% 7%
26%
-28 -28
75% 75%
-9%
- Depreciation and Amortization 8.83 8.83
20% 20%
3%
EBIT (Operating Income) EBIT -37 -37
70% 70%
-12%
Net Profit -64 -64
47% 47%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Adaptive Biotechnologies Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adaptive Biotechnologies Corp Stock News

Neutral
GlobeNewsWire
●
2 days ago
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies
Neutral
GlobeNewsWire
●
15 days ago
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) --  Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026. “Adaptive achieved total company pr...
More Adaptive Biotechnologies Corp News

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Head office United States
CEO Mr. Robins
Employees 624
Founded 2009
Website www.adaptivebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today